Jiangxi Fushine Pharmaceutical Co Ltd

Fuxiang Shares released its 2026 interim report, achieving a turnaround from loss to profit. The company's total operating revenue was 888 million yuan, up 72.59 percent year-on-year. Net profit attributable to the parent company was 177 million yuan, an increase of 184 million yuan compared to the same period last year, marking three consecutive years of growth. Net cash inflow from operating activities was 69.4852 million yuan, up 540.77 percent year-on-year. The company's latest gross profit margin was 39.20 percent, achieving three consecutive quarters and three consecutive years of increase. ROE was 7.49 percent, an increase of 7.80 percentage points from the same period last year.

On the evening of August 11, several A-share listed companies released their 2026 mid-year dividend implementation plans or proposals. Among them, Action Education plans to distribute a cash dividend of 12 yuan per 10 shares, including tax, totaling 143 million yuan. Xinjiang Xintianran Gas plans to distribute 8 yuan per 10 shares, including tax, with an estimated total payout of 339 million yuan. Jangho Group plans to distribute 0.25 yuan per share, including tax, with an estimated total payout of 283 million yuan. Hikvision released its equity distribution implementation announcement, proposing a cash dividend of 5.50 yuan per 10 shares, including tax, to all shareholders, with a cumulative total dividend of 5.041 billion yuan. The record date is August 18. In addition, Yongjin Technology, Wohua Pharmaceutical, Hubei Yihua, Great Wall Sci-Tech, Dongbai Group, and Fushine Pharmaceutical also disclosed their dividend plans.

Bao Jianhua, the controlling shareholder of Jiangxi Fushine Pharmaceutical, has proposed a 2026 interim dividend of 0.5 yuan in cash per 10 shares before tax, with no bonus shares or conversion of capital reserve into share capital. Bao Jianhua, who also serves as the company's actual controller, chairman, and general manager, has pledged to vote in favor at the relevant meeting. The proposal still requires approval by the board of directors before implementation, following a prior shareholder meeting authorization for the board to formulate and execute the 2026 interim profit distribution plan. If the share capital changes before implementation, the total distribution amount will be adjusted based on the same distribution ratio.

As of the close on July 23, 99 A-share biomedical companies have released their 2026 half-year earnings forecasts, with 60 projecting growth in net profit attributable to the parent and 39 forecasting a decline. Fushine Pharma expects net profit attributable to the parent to rise by 2,487 percent to 3,204 percent, Joinn Laboratories anticipates an increase of 884.9 percent to 1,377.4 percent, and Medicilon, Haisco Pharmaceutical, and ST Wanbang also see maximum growth exceeding 500 percent. The chemical pharmaceutical sector is broadly positive, with 25 of the 36 companies that issued forecasts expecting growth. The biologics segment is underperforming, with only 2 of the 9 companies that issued forecasts projecting an increase. Out-licensing of innovative drugs overseas is active, with total out-licensing deal value in the first half reaching approximately 110 billion US dollars. Haisco Pharmaceutical achieved significant performance growth through multiple out-licensing deals. The price of laboratory monkeys continues to rise, with the unit price of cynomolgus monkeys climbing to 178,000 yuan, driving substantial profit forecast increases for CRO companies such as Joinn Laboratories and Medicilon.

As of July 22, 118 ChiNext-listed companies have released their first-half earnings forecasts, with 88 expecting profit growth, accounting for 74.58 percent. A total of 97 companies issued positive forecasts, representing 82.20 percent. Based on the median estimated net profit growth, 51 companies expect growth exceeding 100 percent, while 26 anticipate growth between 50 and 100 percent. Longsys posted the highest median net profit growth estimate at 68,298.99 percent, followed by Fushine Pharmaceutical and Tianhua New Energy with growth of 2,845.50 percent and 2,578.97 percent respectively. Companies expecting profits to double are mainly concentrated in electronics, electrical equipment, and machinery sectors, with 15, 9, and 6 stocks respectively. In terms of market performance, stocks expecting profits to double have risen an average of 49.43 percent this year, with Xingyun Technology, International Composites, and Changchuan Technology leading the gains at 395.23 percent, 325.90 percent, and 214.03 percent respectively.

As of July 13, 45 ChiNext-listed companies have released their first-half earnings previews. Among them, 37 forecast profit growth and 4 expect to turn profitable, bringing the combined positive ratio to 91.11 percent. Based on the median estimated net profit growth, 25 companies are projecting increases exceeding 100 percent. Longsys leads with a surge of 68,298.99 percent, followed by Fushine Pharmaceutical and Tianhua New Energy in second and third place with gains of 2,845.50 percent and 2,578.97 percent respectively. Stocks expected to double their earnings are concentrated in sectors such as electronics, power equipment, and computing, with 9, 4, and 3 names respectively. In terms of market performance, these doubling stocks have risen by an average of 85.93 percent year-to-date. Xingyun Technology, Changchuan Technology, and Han's CNC led the gains, surging 359.82 percent, 247.92 percent, and 183.69 percent respectively.